Abstract:No effective treatment that would reduce the incidence and severity of radiation-induced skin toxicity has been identified up to now. Epigallocatechin-3-gallate (EGCG), which helps in the healing process of erythema response evoked by UV radiation in human, may also alleviate symptoms of radiation dermatitis. We hypothesized that topical EGCG is effective in treating radiation dermatitis and conducted a single-arm phase 2 trial testing this hypothesis with patients undergoing adjuvant radiation therapy to the breast. Patients were treated with mastectomy followed by adjuvant radiation therapy (total dose, 50Gy) to the breast. Eligible patients were also required to have met the following criteria: age≥18 years; ECOG PS 0-1; no prior radiation to the thorax; adequate hematologic, hepatic function and renal values. The study was approved by the Institutional Review and Ethical Committees and registered at ClinicalTrials.gov. In addition, informed consent was obtained from all patients. Topical EGCG at 660μmol/L was applied daily, starting on the day only after the skin becomes grade I dermatitis and ending 2 weeks post-radiation therapy. Patients underwent weekly skin assessments throughout radiation therapy and at 2 weeks after RT-treatment. Outcome measures were assessed using an observer-assessment score that was defined by Radiation Therapy Oncology Group (RTOG) criteria and a self-assessment score that evaluated skin symptoms according to the adapted Skin Toxicity Assessment Tool (STAT). RT was delivered without treatment breaks to all 49 patients. Grade I dermatitis appeared in 17 patients during the second week, 24 during the third week, and 8 during the fourth week. In addition, the mean duration of EGCG treating time is 5 weeks. The personal maximum skin toxicity observed during the course of treatment was follows: Grade 1 toxicity, 71.4% (35 patients); Grade 2 toxicity, 28.6% (14 patients); more than Grade 2 toxicity, 0% (0 patients). Most importantly, the personal minimum skin toxicity received Grade 0 in 15 patients. There was a significant difference between onset and end of the study (P<0.05) in RTOG score. Patient-reported symptom scores were also significantly decreased at the end of the study in pain, burning, itching, and tenderness (P<0.05). It is possible for EGCG to significantly and continuously control the symptoms of pain (85.7% of patients), burning (89.8%), itching (87.8%), pulling (71.4%), and tenderness (79.6%). Topical EGCG treating the radiation-induced dermatitis is effective. Randomized controlled trials will establish to support the use of EGCG for the prevention and management of acute radiation skin reactions.

Clinical Effect of Moisturized Skin Care on Radiation Dermatitis of Head and Neck Cancer

Prophylactic NS-21 maintains the skin moisture but does not reduce the severity of radiation dermatitis in patients with head and neck cancer: a randomized control trial

Preliminary Experience with a Cleansing Mousse and a Non-Steroidal Emulsion for the Prevention and Treatment of Acute Radiation Dermatitis in Breast Cancer Patients Undergoing Adjuvant Radiotherapy

Promoting Comfort: A Clinician Guide and Evidence-Based Skin Care Plan in the Prevention and Management of Radiation Dermatitis for Patients with Breast Cancer

Topical Prevention of Radiation Dermatitis in Head and Neck Cancer Patients: A Network Meta-analysis

Efficacy of Supportive Care for Radiodermatitis in Patients with Head and Neck Cancer: Supplementary Analysis of an Exploratory Phase II Trial

The effect of various interventions on the prevention of radiation dermatitis: a network meta-analysis

Evaluation of the Therapeutic Effect of Preventive External Application of Traditional Chinese Medicine Gel Combined with Psychological Care in Tumor Patients with Radiation Dermatitis

Prevention of radiation induced dermatitis in head and neck cancer patients using cryptomphalus aspersa secretion

Prospective Evaluation of Skin Toxicities in Patients Receiving Post-Mastectomy Irradiation of Chest Wall, Supra/infraclavicular and Internal Mammary Nodes Delivered by Conventional Versus Intensity-Modulated Radiotherapy Technique

Topical Prevention of Radiation Dermatitis in Breast Cancer Patients: A Network Meta-analysis of Randomized Controlled Trials

What is the appropriate skin cleaning method for nasopharyngeal cancer radiotherapy patients? A randomized controlled trial

Comparison of liposomal gel with and without addition of chamomile for prevention of radiation dermatitis in head and neck cancer patients: A randomized controlled trial

Keratin-based topical cream for radiation dermatitis during head and neck radiotherapy: a randomised, open-label pilot study

Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis

Effectiveness of topical corticosteroids on the prevention of acute radiation dermatitis in patients with breast cancer: An updated systematic review and meta-analysis

Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial

Trial of Assessing the Effectiveness of Topical Epigallocatechin-3-Gallate As an Interventional Agent for Radiation-Induced Acute Skin Toxicity to the Breast in Women Undergoing Adjuvant Radiation Therapy

Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review